Showing results (71-80 of 81) with videos related to
Sort By:
Pageof 9
Journal of Immunology (Baltimore, Md. : 1950)|October 23, 2002
Vaccination of macaques with long-standing SIVmac251 infection lowers the viral set point after cessation of antiretroviral therapyElzbieta Tryniszewska, Janos Nacsa, Mark G Lewis, et al.The Journal of Molecular Diagnostics : JMD|July 6, 2011
Multiplex mutation screening by mass spectrometry evaluation of 820 cases from a personalized cancer medicine registryCarol Beadling, Michael C Heinrich, Andrea Warrick, et al.The Journal of Clinical Investigation|May 17, 2013
PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cellsErin E West, Hyun-Tak Jin, Ata-Ur Rasheed, et al.NPJ Precision Oncology|March 27, 2021
Characterizing advanced breast cancer heterogeneity and treatment resistance through serial biopsies and comprehensive analyticsAllen Li, Jamie M Keck, Swapnil Parmar, et al.Cancer Research Communications|June 11, 2026
Predicting clinical sensitivities of PDGFRA exon 18 mutations to imatinib and avapritinib to optimize gastrointestinal stromal tumor treatmentHomma M Khosroyani, Alina Teuber, Ajia Town, et al.Biorxiv : the Preprint Server for Biology|May 7, 2024
Epithelial IL-2 is critical for NK cell-mediated cancer immunosurveillance in mammary glandsLei Wang, Chandra K Maharjan, Nicholas Borcherding, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 11, 2015
Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trialAriel Lopez-Chavez, Anish Thomas, Arun Rajan, et al.Nature|April 5, 2019
Innate lymphoid cells support regulatory T cells in the intestine through interleukin-2Lei Zhou, Coco Chu, Fei Teng, et al.Nature Communications|March 9, 2017
MAX inactivation is an early event in GIST development that regulates p16 and cell proliferationInga-Marie Schaefer, Yuexiang Wang, Cher-Wei Liang, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 19, 2013
Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skinF Stephen Hodi, Christopher L Corless, Anita Giobbie-Hurder, et al.Pageof 9